Multiparametric Magnetic Resonance Imaging in the Detection of Prostate Cancer

Authors
T. Durmus, A. Baur, B. Hamm

Affiliation
Charité Universitätsmedizin Berlin, Department of Radiology, Berlin

Abstract
Prostate cancer is the most common malignancy in men, but only about 10% of patients die from that cancer. Recent studies suggest that not all patients benefit from a radical therapeutic approach. When prostate cancer is suspected, magnetic resonance imaging (MRI) can make an important contribution to cancer localization within the prostate. Many studies show that T2-weighted morphologic imaging should be supplemented by multiparametric MRI techniques including diffusion-weighted imaging, contrast-enhanced sequences, and MR spectroscopy. This approach detects aggressive prostate cancer with high sensitivity and specificity. The findings of multiparametric MRI additionally contribute information to the assessment of cancer aggressiveness. The use of these multiparametric MRI techniques will gain an increasing role in the clinical management of prostate cancer patients. They can help in establishing a definitive diagnosis with a minimum of invasiveness and may also contribute to optimal individualized treatment. This review article presents the different techniques of multiparametric MRI and discusses their contribution to the detection of prostate cancer. Moreover, this review outlines an objective approach to image interpretation and structured reporting of MRI findings using the PI-RADS criteria. The review concludes with an outline of approaches to prostate biopsy on the basis of MRI (transrectal ultrasound, direct MRI guidance of tissue sampling, and MRI-ultrasound fusion biopsy) and emerging future uses of MRI in the planning of focal treatment options and in the active surveillance of patients diagnosed with prostate cancer.

Citation Format:

Zusammenfassung
Multiparametric MRI refers to the combination of morphological sequences and functional imaging techniques. Standard T2-weighted (T2w) and T1-weighted (T1w) turbo-spin-echo sequences are used for visualization of the morphology while diffusion-weighted imaging (DWI), dynamic contrast-enhanced imaging (DCE) and MR spectroscopic imaging can be combined for the functional sequences.

Morphological imaging (T2- and T1-weighted imaging)

High-resolution axial T2-TSE is the backbone of every MR image of the prostate. This is typically supplemented by a sagittal and possibly a coronal T2-TSE sequence which facilitates evaluation of the seminal vesicle in particular. T2-weighted (T2w) imaging allows precise visualization of the zonal anatomy of the prostate with a peripheral and central zone and a transition zone (Fig. 1a). Moreover, nodular, glandular, stromal, and cystic changes in benign prostate hyperplasia (BPH) can be reliably visualized (Fig. 1b). Prostate carcinomas can be detected in T2w imaging on the basis of their low-signal, classic oval shape as well as their space-occupying nature once they reach a certain size (Fig. 2, 3). The diagnostic accuracy of T2w imaging alone is highly variable according to the literature. This is primarily due to the differences in study design (e.g. prostatectomy versus biopsy as reference standard, type of reading, detection versus staging) and in the examined study population (e.g. patients with known prostate cancer versus patients after multiple biopsies). For T2w imaging without functional sequences, the sensitivity and specificity for prostate cancer are approximately 57 – 83 % and 62 – 82 % [6, 7]. The diagnostic limitations of T2w imaging alone are due to the often similar nature of regularly occurring acute and chronic inflammation of the prostate and hemorrhages, which also cause a hypointense pattern in T2w imaging. Prostatitis typically has a striated, slightly hypointense appearance and sometimes cannot be morphologically differentiated from prostate cancer in T2w imaging (Fig. 4, 5). Hemorrhages have a very variable appearance in T2w imaging and can be detected in T1w imaging on the basis of their hyperintensity (Fig. 6a, b). Bleeding is a regular occurrence after biopsy. Therefore, MRI of the prostate should not be performed until at least 6 – 8 weeks after biopsy to avoid unnecessary diagnostic impediments. However, hemorrhages can also persist for several months. Therefore, it is useful to know that bleeding can also serve as a diagnostic aid for detection. In a prostate that is hyperintense in T1w imaging due to post-biopitic hemorrhagic changes, hypointense island-like areas on the T1w images that correlate with areas that are hypointense on the T2w images can be an indication of prostate cancer (hemorrhage exclusion sign) [8]. It is presumed that the anticoagulative effect of the citrate which is highly concentrated in normal prostate tissue but is low in cancer tissue results in increased bleeding. Well vascularized and perfused cancer tissue is probably also a better site of degradation for bleeding residues than normal prostate tissue. With respect to a more exact diagnosis in the case of bleeding residues, diffusion-weighted imaging and MR spectroscopy have proven to be advantageous in

Introduction

Prostate cancer is the most common malignancy in men, but only about 10 % of patients die from that cancer. While the incidence rate in the last 30 years has increased four-fold, the mortality rate has decreased over the last 20 years [1]. This can be primarily attributed to the early detection of prostate cancer as a result of the common practice of testing the prostate-specific antigen (PSA) in the peripheral blood. Trendsetting studies indicate that the current diagnostic and therapeutic approach must be fundamentally rethought. Wilt et al. could not show a significant reduction in the mortality rate for patients with a localized tumor who underwent a radical prostatectomy compared to patients who were simply monitored [2]. In addition to possible postoperative complications, radical prostatectomy was associated with a significantly higher morbidity rate (incontinence, erectile dysfunction) [2]. Like radical prostatectomy, radiation therapy is also associated with significant side effects, such as loss of potency, in up to 50 % of patients [3]. Although prostate cancer can be effectively treated in many cases by radical therapies in the case of early diagnosis, not all patients seem to benefit from such treatments. Therefore, new management strategies, such as active surveillance and watchful waiting, as well as organ-preserving focal therapy options are currently being evaluated in studies.

Selecting the most suitable diagnostic and therapeutic approach for the individual patient is a significant challenge. As a matter of fact, MRI with its multiparametric imaging is shaking the foundations of established diagnostic and therapeutic paradigms and is now being used for the planning of diagnostic punctures and radical treatments. In the future it will become increasingly important for patient stratification with regard to therapeutic approach and treatment monitoring [4].

The following provides an overview of the current status of multiparametric MRI of the prostate and an interpretation of relevant findings. The role of multiparametric MRI in the diagnosis of prostate cancer including systematic and targeted biopsy and its potential in conservative and minimally invasive treatments will also be discussed.

Multiparametric MRI of the prostate

Due to its high soft tissue contrast, high resolution, and ability to simultaneously image functional parameters, MRI provides the best visualization of the prostate compared to other imaging methods. In the case of MRI scanners with a field strength of 1.5 T, it has proven to be advantageous to use a dedicated endorectal coil particularly for the local staging of prostate cancer [5]. In the case of MRI scanners with a field strength of 3 T and the associated higher signal-to-noise ratio, the image quality is so good even without an endorectal coil that the coil is not necessary for detection purposes. This should result in greater patient acceptance and should further support the broader use of multiparametric MRI in the coming years.

Morphological imaging (T2- and T1-weighted imaging)

High-resolution axial T2-TSE is the backbone of every MR image of the prostate. This is typically supplemented by a sagittal and possibly a coronal T2-TSE sequence which facilitates evaluation of the seminal vesicle in particular. T2-weighted (T2w) imaging allows precise visualization of the zonal anatomy of the prostate with a peripheral and central zone and a transition zone (Fig. 1a). Moreover, nodular, glandular, stromal, and cystic changes in benign prostate hyperplasia (BPH) can be reliably visualized (Fig. 1b). Prostate carcinomas can be detected in T2w imaging on the basis of their low-signal, classic oval shape as well as their space-occupying nature once they reach a certain size (Fig. 2, 3). The diagnostic accuracy of T2w imaging alone is highly variable according to the literature. This is primarily due to the differences in study design (e.g. prostatectomy versus biopsy as reference standard, type of reading, detection versus staging) and in the examined study population (e.g. patients with known prostate cancer versus patients after multiple biopsies). For T2w imaging without functional sequences, the sensitivity and specificity for prostate cancer are approximately 57 – 83 % and 62 – 82 % [6, 7]. The diagnostic limitations of T2w imaging alone are due to the often similar nature of regularly occurring acute and chronic inflammation of the prostate and hemorrhages, which also cause a hypointense pattern in T2w imaging. Prostatitis typically has a striated, slightly hypointense appearance and sometimes cannot be morphologically differentiated from prostate cancer in T2w imaging (Fig. 4, 5). Hemorrhages have a very variable appearance in T2w imaging and can be detected in T1w imaging on the basis of their hyperintensity (Fig. 6a, b). Bleeding is a regular occurrence after biopsy. Therefore, MRI of the prostate should not be performed until at least 6 – 8 weeks after biopsy to avoid unnecessary diagnostic impediments. However, hemorrhages can also persist for several months. Therefore, it is useful to know that bleeding can also serve as a diagnostic aid for detection. In a prostate that is hyperintense in T1w imaging due to post-biopitic hemorrhagic changes, hypointense island-like areas on the T1w images that correlate with areas that are hypointense on the T2w images can be an indication of prostate cancer (hemorrhage exclusion sign) [8]. It is presumed that the anticoagulative effect of the citrate which is highly concentrated in normal prostate tissue but is low in cancer tissue results in increased bleeding. Well vascularized and perfused cancer tissue is probably also a better site of degradation for bleeding residues than normal prostate tissue. With respect to a more exact diagnosis in the case of bleeding residues, diffusion-weighted imaging and MR spectroscopy have proven to be advantageous in
At present, morphological imaging should normally be combined with at least two functional sequences in order to significantly increase the sensitivity and specificity of MRI [11–13]. These will be introduced in the following.

**Diffusion-weighted imaging**

Diffusion-weighted imaging visualizes the Brownian molecular motion of water. It has become an important part of oncological imaging since malignant tumors are typically comprised of densely arranged cells whose numerous cell membranes limit this Brownian molecular motion [14]. Prostate cancers are thus visualized on highly diffusion-weighted images (typically upper b-values of 800–1000 s/mm² in prostate imaging) as areas with high signal intensity (Fig. 7a). Diffusion coefficients (apparent diffu-
sion coefficient, ADC) can be calculated from the diffusion-weighted data. In the ADC maps, areas with normal diffusion can then be differentiated as having high signal intensity and those with diffusion restriction as having comparatively low signal intensity (Fig. 7b). Most studies showed that DWI is a very useful addition to morphological imaging and can increase sensitivity in particular by 10 – 25% [15 – 17]. Since hyperplastic stromal nodules can have pronounced diffusion restriction in BPH, DWI must be evaluated together with morphological imaging (T2w) especially when assessing the central portions of the prostate gland [16]. Studies in recent years have increasingly examined the capabilities of DWI with respect to evaluating the aggressiveness of prostate cancer. It was able to be shown that the ADC value has a negative correlation with the Gleason score, i.e., low ADC values are seen primarily in high-grade aggressive prostate cancers [15, 18]. Results regarding the ability to differentiate low-grade tumors (Gleason score 3 + 3 = 6) and high-grade tumors (Gleason score > 4 + 3 = 7) in the peripheral zone are very promising since they may be able to help to better determine patient risk potential [19, 20]. However since there can still be relevant overlapping of the ADC values in the different Gleason groups, additional studies are needed to implement this grading potential of diffusion-weighted imaging in the clinical routine. However, DWI will play an important role in differentiating patients with a low risk from those with a high risk and separating them with respect to management [21].

**Dynamic contrast-enhanced (DCE) MRI**

Contrast-enhanced MRI sequences can be used to assess the vascularity and permeability of tissues. Gadolinium-containing extracellular T1w contrast agent is typically administered intravenously for this purpose [22]. Fast T1w gradient echo sequences with a temporal resolution of 4 – 10 seconds are primarily used in prostate imaging. Measurements should be performed over a period of up to approximately 5 minutes after contrast agent application [13]. The enhancement can be displayed in the form of curves over time thus helping to characterize tissues. Prostate cancers are characterized by fast wash-in (early peak enhancement) and fast wash-out compared to healthy tissue (type III curve). Enhancement typically increases steadily (type I) in the given measurement time in cancer-free tissue, while a curve with a plateau (type II) occurs relatively frequently both in healthy tissue and in cancer tissue [22]. On the basis of enhancement curves, gadolinium concentrations in tissue and tissue transport constants in the direction of the tumor interstitium (Ktrans) and back in the direction of the blood plasma (Kep) can be calculated using suitable mathematical models (two-compartment Tofts model). Prostate cancers are characterized by an increase in the tissue transport constants which can be displayed using color coding in pharmacokinetic parameter maps (Fig. 8) [23]. The currently available studies do not provide a clear conclusion regarding the improvement of prostate cancer detection via DCE. Some studies were able to show an improvement of the diagnostic accuracy of conventional MRI (T2w and T1w) when supplemented by DCE imaging [24, 25]. However, it is problematic in the case of DCE that hyperplastic nodules in BPH can enhance and wash out quickly like prostate carcinoma foci and Ktrans and Kep can be accordingly increased, thus limiting the sensitivity and specificity of DCE in the central portions of the prostate gland in particular [26, 27]. In addition, inflammation can often have greater vascularity and tissue permeability, which also limits the sensitivity and specificity of DCE for the detection of prostate cancer. However, it was able to be shown that the local staging of prostate cancer and the detection of local tumor relapses after definitive therapy can be significantly improved using dynamic T1w sequences with good temporal resolution [28, 29].

**MR spectroscopy**

MR spectroscopy allows spatially resolved visualization of chemical substances in an organ. The healthy prostate gland produces an ample amount of a citrate-containing secretion, resulting in a high citrate content and a low choline level. In the case of prostate cancer, the choline level is significantly elevated and the citrate content is reduced due to the metaplastic processes of the cell membranes. The relationship between these two metabolites can therefore be used as a measure of malignancy [30]. MR spectroscopy increases the specificity of the MRI examination in particular,
but can also be used to evaluate tumor volume [31, 32]. The diagnostic accuracy of the morphological MRI examination can be increased by MR spectroscopy from 52 % to 75 % [10]. The basic requirement for good spectral resolution of the individual metabolites is a homogeneous magnetic field in the field of measurement and sufficient suppression of the fat and water signal during the measurement. In addition to sequence adjustments, this usually requires multiple shim- ming steps and saturation bands around the prostate to be manually adjusted to the individual prostate anatomy. Together with these preparations, MR spectroscopy at 1.5 T requires a measurement time of 13 – 20 minutes. Evaluation and interpretation are complex and often only possible after appropriate physical adjustments. Even if automatic segmentation algorithms are able to automatically detect the prostate in the near future thus minimizing measurement preparations, MR spectroscopy will remain limited in its daily use due to the significant time investment and the high level of physical-medical expertise required.

Structured interpretation and communication of MRI findings in the prostate (MR PI-RADS)

In 2012 the European Society of Urogenital Radiology (ESUR) created the Magnetic Resonance Prostate Imaging Reporting and Data System (MR PI-RADS) as part of its MRI guidelines for prostate imaging [13]. Based on the breast imaging reporting and data system (BI-RADS), a standardized method for reporting multiparametric MRI of the prostate for the detection of prostate cancer is proposed here. The goal was to standardize image interpretation and to simplify communication between the radiologist and colleagues in other departments.

Based on clearly defined criteria according to PI-RADS, every lesion suspicious for tumor within the prostate is assigned a point value between 1 and 5 for every sequence performed as part of multiparametric MRI (consisting of at least T2w, DWI, and DCE). Moreover, a total point value is calculated for every lesion suspicious for tumor [33]. Thus, a statement regarding the probability of the presence of a clinically significant prostate cancer should be possible: A point value of 1 means that a lesion is probably benign, while a point value of 5 indicates a high probability of malignancy. The development of PI-RADS and the criteria contained therein for the assignment of point values are based on published literature and an expert consensus. Since being published in February 2012, PI-RADS has been evaluated in multiple studies. The point values of T2w, DWI, and DCE were added to form a total point value for lesions suspicious for tumor. Good and reproducible diagnostic accuracy was documented for the total point values calculated in this manner [33 – 37]. Standardization of image interpretation in research and the clinical routine is an important milestone that should accelerate the acceptance of multiparametric MRI in the coming years. The results of clinical studies should be easier to compare using PI-RADS. Moreover, PI-RADS makes it possible to formulate guidelines for diagnostic clarification and perhaps even for the treatment of prostate cancer. The present data indicates that a biopsy should be performed in the case of lesions with PI-RADS ≥ 4 while monitoring via MRI and PSA could be sufficient in lesions with PI-RADS ≤ 3.

MRI and prostate biopsy

The standard prostate biopsy is the transrectal ultrasound (TRUS)-guided systematic prostate biopsy. Urological stud-
ies in particular have shown that the detection rate increases as expected with the number of samples so that approximately 6 samples are currently taken from each lateral lobe in accordance with the recommendations of the professional associations [38, 39]. However, the entire context of the diagnostic weaknesses of TRUS biopsy only becomes clear with MR imaging and visualization of prostate cancer [40]. The rate of carcinomas in the ventral portion of the prostate gland as well as in an extreme lateral position in the peripheral zone and on the apex of the gland is significant in patients with multiple negative ultrasound-guided biopsies. It was shown that patients with a diagnosis of prostate cancer in the ventral portions of the gland by direct MRI-guided biopsy have a higher clinical risk than those with a diagnosis of prostate cancer in the peripheral zone [41].

**Direct MRI-guided biopsies**

All direct MRI-guided biopsy techniques have in common that MRI is performed during the biopsy and the images are used to guide the biopsy needle. Therefore, the biopsy equipment must be MRI-compatible. MRI-guided biopsies should be performed on a 1.5 T or 3 T unit since exact visualization of the lesions during biopsy is of essential importance. Direct MRI-guided biopsies can be performed via transgluteal, transperineal, and transrectal access [41 – 43]. Transrectal biopsy is the most common and most accepted direct MRI-guided biopsy technique since there are no special requirements regarding anesthesia or sterility in contrast to the transperineal and transgluteal methods. Transrectal MRI-guided biopsy is typically performed after simply coating the rectal mucous membrane with a disinfecting and locally anesthetizing gel [44]. The patient is premedicated with antibiotics as in standard transrectal ultrasound-guided biopsies. Transrectal MRI-guided biopsy can be evaluated as the most exact prostate biopsy method on the basis of the present data (Fig. 9): In populations with multiple negative systematic ultrasound-guided biopsies detection rates of 41 – 59% could be achieved with direct MRI-guided prostate biopsy with the majority of the tumors being classified as clinically relevant [41, 45 - 47]. As shown in Fig. 9, the targeted clarification of non-clinically relevant cancers is also important since this can resolve the diagnostic dilemma of an increasing PSA with a negative biopsy thus creating a foundation for noninvasive and minimally invasive strategies, such as active surveillance or focal therapy.

**MRI/ultrasound fusion biopsy**

A multiparametric MRI scan is performed prior to every targeted biopsy to identify lesions that are suspicious for carcinoma and to evaluate whether targeted biopsy techniques are suitable. A possibility to improve reporting would be to create a drawing of the location of the suspicious focus in addition to the written findings. This drawing can then be used during a planned biopsy to perform a greater number of biopsies in certain regions of the prostate. The procedure is similar for cognitive fusion in which ultrasound-guided biopsy is performed immediately after viewing the MRI scan. The objective here is to evaluate the regions suspicious on MRI in a targeted manner and to identify focal lesions on the B-mode image [48]. The prostate must be viewed in both modalities on the same (or at least comparable) image plane. Otherwise, it is extremely difficult to recognize complex structures in the prostate. Navigation is facilitated by detection of the urethra, prominent hyperplastic nodules, or cysts. Peuch et al. were able to detect 15 % more clinically relevant cancers per TRUS biopsy in their study by viewing the MRI images immediately prior to biopsy [48]. However, the cognitive fusion can be expected to be highly examiner-dependent. Therefore, software-based fusion of MRI datasets with ultrasound images would be desirable. Software on the latest ultrasound devices can fuse previously imported MRI datasets three-dimensionally and in real time with the B-mode image of an ultrasound examination. An electromagnetic unit that is coupled to the ultrasound probe and can track the movements of the probe is positioned next to the patient table during the biopsy for this purpose [48, 49]. By selecting individual reference points on the MRI images and the B-mode image, the MRI images are adjusted and moved in parallel with the ultrasound scan (Fig. 10). This makes it possible to use the ultrasound probe to navigate to and biopsy lesions evaluated as suspicious for cancer in the preceding multiparametric MRI scan [48]. Software-supported 3D real-time fusion is currently under intense evaluation. Multiple workgroups were already able to document a significantly higher detection rate of clinically relevant prostate cancers compared to systematic ultrasound-guided biopsy [49 – 51].

To date, the different direct MRI-guided biopsy techniques and MRI/ultrasound fusion biopsy have not been evaluated in a direct comparison with respect to MRI preparation and examination time, cost, and diagnostic accuracy. However, the possibility of software-based fusion of MRI and ultrasound images in real time is a milestone in the biopsy diag-

---

**Fig. 9**

- **a** Patient with a negative ultrasound-guided biopsy in history and increasing PSA value; 12 ng/ml at the time of MRI. Coronal T2 TSE with lesion suspicious for cancer measuring a maximum of 5 × 7 mm in the peripheral zone.
- **b** Targeted biopsy under direct MRI guidance yielded a total sample length of 12 mm with 4 mm of an acinar prostate adenocarcinoma (Gleason score 3 + 3 = 6).
nosis of prostate cancer and will probably be used more widely in coming years.

MRI for active surveillance

Not all patients with prostate cancer benefit from radical surgery or radiation therapy, in particular under consideration of possible peri- and post-therapeutic complications including incontinence and erectile dysfunction [2]. In particular, patients with low-grade prostate cancer (Gleason ≤ 6) can benefit from surveillance and watchful waiting. Multiparametric MRI can play a significant role in identifying suitable patients [52]. In the case of patients under surveillance, multiparametric MRI can help in the follow-up period to detect paraclinical parameters, such as PSA value and results of a rebiopsy, as well as any tumor progress and to initiate appropriate treatment. Such progress can be detected on the basis of an increase in size but in the future also on the basis of changes in functional sequences like DWI and DCE in terms of dedifferentiation. MRI could also significantly reduce the number of necessary rebiopsies, thus making management less invasive for patients. To date, multiparametric MRI has not been an integral part of diagnostic algorithms of large prospective studies for examining morbidity and mortality among patients under watchful waiting or active surveillance. However, the role of multiparametric MRI is being explicitly examined in studies currently in progress regarding this topic. Corresponding evidence-based data can therefore be expected in the near future.

MRI and minimally invasive therapies

A number of minimally invasive, focal, organ-preserving methods have been used in recent years as further alternatives to the radical treatment of prostate cancer. The goal of these methods is to ablate tumor tissue within the prostate while maintaining tumor-free areas of the prostate gland and preserving the periprostatic tissue and structures. These procedures seek to avoid typical peri- and postoperative complications. From the histopathological processing of prostatectomy specimens, it is known that prostate cancer is usually multifocal. However, a so-called “index lesion”, a tumor focus that is significant on the basis of size and differentiation (Gleason score), seems to be decisive for patient prognosis also in these patients [53]. The goal of a minimally invasive treatment must therefore not necessarily be to achieve tumor-free status but to ablate significant tumor foci. Imaging per multiparametric MRI makes it possible to determine the exact location of relevant tumor foci in order to thus guide focal therapies as in diagnostic biopsies [54]. The methods used to date for the prostate include cryotherapy, high-intensity focused ultrasound, and laser-induced thermoablation [55]. Other methods, such as irreversible electroporation (IRE), are currently being evaluated in studies [56]. Significant tumor foci that are generally accessible for ablation can be identified via multiparametric MRI. Moreover, MRI will become increasingly important in the image-guided use of locally ablative procedures [54, 55]. The PSA value remains a valuable marker for follow-up evaluation and for detecting relapses. The exact role that multiparametric MRI will play in treatment monitoring after minimally invasive therapy and as an instrument in long-term follow-up must be examined in the coming years.

References

Durmus T et al. Multiparametric Magnetic Resonance Imaging... Fortschr Röntgenstr 2014; 186: 238–246
antigen and repeated, negative, random, systematic, transrectal ultra-
sound biopsies: detection of clinically significant prostate cancers. Eur
Urol 2012; 62: 902–909. DOI: 10.1016/j.eururo.2012.01.047 S0302-
2838(12)00123-6 [pii]
47 Roethke M, Anastasiadis AG, Lichy M et al. MRI-guided prostate biopsy
detects clinically significant cancer: analysis of a cohort of 100 patients
DOI: 10.1007/s00345-011-0675-2
48 Puech P, Rouviere O, Renard-Penna R et al. Prostate cancer diagnosis:
multiparametric MR-targeted biopsy with cognitive and transrectal
US-MR fusion guidance versus systematic biopsy – prospective multi-
13121501 radiol.13121501 [pii]
49 Durmus T, Stephan C, Grigoryev M et al. Detection of prostate cancer by
real-time MR/ultrasound fusion-guided biopsy: 3T MRI and state of
DOI: 10.1055/s-0032-1330704
50 Sonn GA, Chang E, Natarajan S et al. Value of Targeted Prostate Biopsy
Using Magnetic Resonance-Ultrasound Fusion in Men with Prior Neg-
ative Biopsy and Elevated Prostate-specific Antigen. Eur Urol 2013;
DOI: S0302-2838(13)00249-2 [pii] 10.1016/j.eururo.2013.03.025
51 Walton-Diaz A, Hoang AN, Turkbey B et al. Can MR-US Fusion Biopsy
DOI: S0022-5347(13)04619-3 [pii] 10.1016/j.juro.2013.05.118
52 Lees K, Durie M, Parker C. Active surveillance in prostate cancer.
b013e328351dc47
53 Wise AM, Stamey TA, McNeal JE et al. Morphologic and clinical signifi-
cance of multifocal prostate cancers in radical prostatectomy speci-
mens. Urology 2002; 60: 264–269. DOI: S0090429502017284 [pii]
54 de la Rosette J, Ahmed H, Barentsz J et al. Focal therapy in prostate
Cancer—report from a consensus panel. Journal of endourology/Endouro-
logical Society 2010; 24: 775–780. DOI: 10.1089/end.2009.0596
55 Bomers JC, Sedelaar JP, Barentsz JO et al. MRI-guided interventions for
56 van den Bos W, Muller BC, de la Rosette JJ. A randomized controlled trial
on focal therapy for localized prostate carcinoma: hemiablation versus
complete ablation with irreversible electroapotation. Journal of en-
dourology/Endourological Society 2013; 27: 262–264. DOI: 10.1089/
end.2013.1568

Durmus T et al. Multiparametric Magnetic Resonance… Fortschr Röntgenstr 2014; 186: 238–246